Evidence map›Paper›PMID 41071929›Full record

ArticleG3 (Bethesda, Md.)2026

Identification of susceptibility loci using a novel murine model for triple-negative breast cancer.

Minjeong Kim, Logan G McGrath, Zeid T Mustafa, Samson Eugin Simon, Naveed Pervaiz, Emily W Grey, Sydney C Joseph, Emily Korba, Sandesh J Marathe, Margaret S Bohm and 12 more

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Minjeong KimDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.ORCID 0000-0003-1825-436X
Logan G McGrathDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.ORCID 0009-0008-2964-1828
Zeid T MustafaDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Samson Eugin SimonDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.ORCID 0000-0003-0710-3857
Naveed PervaizDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Emily W GreyDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.ORCID 0000-0003-1153-7471
Sydney C JosephDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Emily KorbaDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Sandesh J MaratheDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Margaret S BohmDepartment of Microbiology, Immunology, and Biochemistry, UTHSC, Memphis, TN 38163, United States.
Arvind V RameshDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Sidharth S MahajanDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Casey J BohlDepartment of Genetics, Genomics, and Informatics, UTHSC, Memphis, TN 38163, United States.
Pjotr PrinsDepartment of Genetics, Genomics, and Informatics, UTHSC, Memphis, TN 38163, United States.
Robert W ReadDepartment of Genetics, Genomics, and Informatics, UTHSC, Memphis, TN 38163, United States.
Jeremiah R HoltDepartment of Genetics, Genomics, and Informatics, UTHSC, Memphis, TN 38163, United States.
D Neil HayesDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.
Lu LuUTHSC Center for Cancer Research, College of Medicine, UTHSC, Memphis, TN 38163, United States.
Robert W WilliamsUTHSC Center for Cancer Research, College of Medicine, UTHSC, Memphis, TN 38163, United States.
Laura M SipeDepartment of Biology, University of Mary Washington, Fredericksburg, VA 22401, United States.
David G AshbrookUTHSC Center for Cancer Research, College of Medicine, UTHSC, Memphis, TN 38163, United States.ORCID 0000-0002-7397-8910
Liza MakowskiDivision of Hematology and Oncology, Department of Medicine, College of Medicine, The University of Tennessee Health Science Center (UTHSC), Memphis, TN 38163, United States.ORCID 0000-0002-5337-8037

Funding

Determining the contribution of microbial-derived metabolites to protective immunity in obesity-driven cancer risk.U01CA272541 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Liza Makowski-Hayes, Joseph F PIERRE · 2022 to 2026
$5.1M
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation CenterUG1CA233333 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, MERKER, JASON DEREK · 2019 to 2025
$4.8M
A Unified High Performance Web Service for Systems Genetics and Precision MedicineR01GM123489 · NIGMS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PRINS, PJOTR, SEN, SAUNAK · 2017 to 2024
$3.7M
Role of microbial-modulated bile acid receptor signaling in breast cancerR01CA253329 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Katherine Loree Cook, Liza Makowski-Hayes · 2020 to 2026
$3.0M
Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical modelR01CA262112 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Liza Makowski-Hayes · 2022 to 2026
$2.0M
Pan-cancer genomic characterization of human papillomavirus associated tumorsF30CA265224 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI HOLT, JEREMIAH R. · 2022 to 2025
$186k
The role of bile acids to ameliorate obesity driven triple negative breast cancerF32CA250192 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SIPE, LAURA MARIE · 2021 to 2022
$80k
American Association for Cancer ResearchNational Institute of Health R01GM123489NCI NIH HHS F30 CA265224NCI NIH HHS F32 CA250192NCI NIH HHS R01 CA253329NCI NIH HHS R01CA253329NCI NIH HHS R01 CA262112NCI NIH HHS R01CA262112NCI NIH HHS U01 CA272541NCI NIH HHS U01CA272541NCI NIH HHS UG1 CA233333NIGMS NIH HHS R01 GM123489Triple Negative Breast Cancer Foundation ResearchUTHSC Center for Cancer ResearchUTHSC College of Graduate Health Sciences Alma and Hal ReaganUTHSC College of Graduate Health Science Summer Research Scholarship
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the deadliest subtype of breast cancer (BC) with few targeted therapies. To identify novel genetic modifiers of TNBC, we created a murine model incorporating high levels of genetic and phenotypic diversity. C3(1)-T-antigen ("C3Tag") mice, which develop spontaneous basal-like TNBC tumors, were systematically crossed with a large set of sequenced BXD recombinant inbred strains to produce isogenic hybrids segregating for C3Tag. The severity of TNBC traits including tumor latency, multiplicity, and survival was highly variable and heritable. We mapped modifiers of TNBC and identified loci on chromosomes 16 and 10 associated with tumor multiplicity and latency, respectively. Candidate genes were prioritized including a lysosomal enzyme involved in cell proliferation, Gns; tumor suppressor Rassf3; and Rab-modifying Tbc1d30. In tumors from BC patients, higher GNS, RASSF3, and TBC1D30 expression associated with poor overall survival. In sum, we developed a clinically relevant, BXD-BC model which provides robust genetic heterogeneity enabling the identification of conserved modifiers and mediators of BC.

Indexed as

Genetic LociGenetic Predisposition to DiseaseQuantitative Trait LociTriple Negative Breast NeoplasmsAnimalsChromosome MappingDisease Models, AnimalFemaleHumansMiceantitumor immunityeQTLgene varianthybridQTLsystems geneticstumor microenvironment

Identifiers

PMID41071929
PMCPMC12869084

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.